Literature DB >> 24787295

Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond.

Kriti Mittal1, John Ebos2, Brian Rini3.   

Abstract

Our understanding of the dynamic tumor microenvironment (TME) has improved exponentially over the last few decades. In addition to traditional cytotoxic agents, anti-cancer strategies now include numerous molecular-targeted drugs that modulate distinct elements of the TME. Angiogenesis is an underlying promoter of tumor growth, invasion, and metastases. From traditional and emerging angiogenic cytokines and their receptors to novel immune checkpoint inhibitors, regulation of the tumor microenvironment is potentially key in countering tumor progression. In this article, an overview of the architecture of the TME and the orchestration of angiogenesis within the TME is provided. Additionally, traditional and novel angiogenic targets of current interest within the TME are reviewed.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24787295     DOI: 10.1053/j.seminoncol.2014.02.007

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  56 in total

1.  A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor.

Authors:  Naomasa Ishida; Takuya Fukazawa; Yutaka Maeda; Tomoki Yamatsuji; Katsuya Kato; Kenichi Matsumoto; Tsuyoshi Shimo; Nagio Takigawa; Jeffrey A Whitsett; Yoshio Naomoto
Journal:  Exp Cell Res       Date:  2015-04-01       Impact factor: 3.905

2.  Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.

Authors:  B R Achyut; Adarsh Shankar; A S M Iskander; Roxan Ara; Kartik Angara; Peng Zeng; Robert A Knight; Alfonso G Scicli; Ali S Arbab
Journal:  Cancer Lett       Date:  2015-09-21       Impact factor: 8.679

3.  Prospero homeobox 1 mediates the progression of gastric cancer by inducing tumor cell proliferation and lymphangiogenesis.

Authors:  Kang-Jin Park; Sung-Bum Cho; Young-Lan Park; Nuri Kim; Sun-Young Park; Dae-Seong Myung; Wan-Sik Lee; Sun-Seog Kweon; Young-Eun Joo
Journal:  Gastric Cancer       Date:  2016-01-12       Impact factor: 7.370

4.  CAR-T cells and combination therapies: What's next in the immunotherapy revolution?

Authors:  Maria C Ramello; Eric B Haura; Daniel Abate-Daga
Journal:  Pharmacol Res       Date:  2017-12-01       Impact factor: 7.658

5.  Myeloid cell leukemia-1 is associated with tumor progression by inhibiting apoptosis and enhancing angiogenesis in colorectal cancer.

Authors:  Wan-Sik Lee; Young-Lan Park; Nuri Kim; Hyung-Hoon Oh; Dong-Jun Son; Mi-Young Kim; Chan-Young Oak; Cho-Yun Chung; Hyung-Chul Park; Jong-Sun Kim; Dae-Seong Myung; Sung-Bum Cho; Hyun-Soo Kim; Young-Eun Joo
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 6.  Growth hormone in the tumor microenvironment.

Authors:  Vera Chesnokova; Shlomo Melmed
Journal:  Arch Endocrinol Metab       Date:  2019 Nov-Dec       Impact factor: 2.309

Review 7.  Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma.

Authors:  Kelly E Craven; Jesse Gore; Murray Korc
Journal:  Cancer Lett       Date:  2015-12-23       Impact factor: 8.679

8.  SCARA5 plays a critical role in the progression and metastasis of breast cancer by inactivating the ERK1/2, STAT3, and AKT signaling pathways.

Authors:  Kai You; Fei Su; Lihua Liu; Xiaohong Lv; Jianguo Zhang; Yafang Zhang; Baoquan Liu
Journal:  Mol Cell Biochem       Date:  2017-05-11       Impact factor: 3.396

9.  Impact of single-nucleotide polymorphisms on radiation pneumonitis in cancer patients.

Authors:  Cheng-Xian Guo; Jing Wang; Li-Hua Huang; Jin-Gao Li; Xiang Chen
Journal:  Mol Clin Oncol       Date:  2015-10-30

Review 10.  Cancer Modeling-on-a-Chip with Future Artificial Intelligence Integration.

Authors:  Kirsten Lee Fetah; Benjamin J DiPardo; Eve-Mary Kongadzem; James S Tomlinson; Adam Elzagheid; Mohammed Elmusrati; Ali Khademhosseini; Nureddin Ashammakhi
Journal:  Small       Date:  2019-11-13       Impact factor: 13.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.